Cisplatin and Vinblastine

The combination of cisplatin and vinblastine is a chemotherapy regimen used to treat various types of cancer. Based on the search results, I can provide comprehensive information about this drug combination.\n\n## Mechanism and Clinical Applications\n\nCisplatin and vinblastine work through different mechanisms to combat cancer cells. Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, interfering with cell division and triggering apoptosis[6]. Vinblastine is a vinca alkaloid that binds to tubulin, preventing microtubule formation and disrupting mitosis[3].\n\nThis combination has demonstrated significant activity in several cancer types:\n\n- **Head and Neck Cancer**: In patients with locally advanced squamous cell carcinoma of the head and neck, the cisplatin-vinblastine combination showed an overall major response rate of 83% (20 out of 24 evaluable patients)[1].\n\n- **Malignant Mesothelioma**: A study of 20 patients with stage IV malignant mesothelioma reported one complete response, four partial responses, and nine stable diseases. The median survival for responders was 19.3 months compared to 5.2 months for non-responders[2].\n\n- **Testicular Cancer**: The combination has been used in bulky seminoma treatment, often alongside other agents like ifosfamide[5].\n\n- **Non-Small-Cell Lung Cancer**: The combination has been administered to patients with stage III non-small-cell lung cancer[7].\n\n## Dosing and Administration\n\nThe dosing regimens vary by cancer type and protocol:\n\n- For head and neck cancer: High-dose cisplatin with frequent vinblastine administration[1].\n- For mesothelioma: Cisplatin 100 mg/m² IV infusion on day 1 and vinblastine 6 mg/m² IV on days 1 and 8, repeated every 4 weeks[2].\n- For seminoma: Vinblastine 6 mg/m² on days 1 and 2, combined with other agents like ifosfamide and cisplatin[5].\n\n## Side Effects\n\nCommon toxicities associated with this combination include:\n\n- Nausea and vomiting (76% of patients in one study)[1]\n- Myelosuppression (72%)[1]\n- Neutropenia, sometimes requiring hospitalization for fever[1]\n- Transient increases in serum creatinine[1]\n\nDespite these side effects, the toxicity profile is generally considered acceptable and manageable[2].\n\n## Related Combinations\n\nThe cisplatin-vinblastine combination is sometimes used as part of larger regimens:\n\n- MVAC: A combination of methotrexate, vinblastine, doxorubicin (Adriamycin), and cisplatin used primarily for urothelial carcinoma, including bladder cancer[3].\n- VIP: A regimen of vinblastine, ifosfamide, and cisplatin used in testicular cancer treatment[5].\n\nThe combination of cisplatin and vinblastine represents an effective chemotherapy option with demonstrated efficacy across multiple cancer types, particularly in advanced disease settings.

Other names

cisplatinum + vinblastinecisplatinum + vinblastine combination therapy